102 related articles for article (PubMed ID: 37657057)
1. Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Liu S; Cheng C; Xu L; Zhao P
Medicine (Baltimore); 2023 Sep; 102(35):e34811. PubMed ID: 37657057
[TBL] [Abstract][Full Text] [Related]
2. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Li D; Zhang C; Yang K; Ma Z; Ma L; Cheng C; Xu L; Wan S
Medicine (Baltimore); 2024 Jan; 103(3):e36865. PubMed ID: 38241568
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Wang L; Lin L; Zhou W
Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Feng J; Zhao Y; Zhai L; Zhou J
Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
[TBL] [Abstract][Full Text] [Related]
5. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38671328
[TBL] [Abstract][Full Text] [Related]
7. Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres
Liang B; Makamure J; Shu S; Zhang L; Sun T; Zheng C
Front Oncol; 2021; 11():576232. PubMed ID: 33796448
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Lenvatinib in Combination With PD-1 Monoclonal Antibody and Interventional Treatment for Intermediate-Stage Hepatocellular Carcinoma: Impact on Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Levels: A Retrospective Study.
Zhu J; Wu Y; Zhang H; Yang J; An Y; Shao S; Xia N
Technol Cancer Res Treat; 2024; 23():15330338241256812. PubMed ID: 38802996
[No Abstract] [Full Text] [Related]
10. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.
Ma KP; Fu JX; Duan F; Wang MQ
World J Gastrointest Oncol; 2024 Apr; 16(4):1236-1247. PubMed ID: 38660650
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
[TBL] [Abstract][Full Text] [Related]
12. Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Pan D; Liu H; Qu P; Chen X; Ma X; Wang Y; Qin X; Han Z
J Gastrointestin Liver Dis; 2024 Mar; 33(1):85-93. PubMed ID: 38554419
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
Hou C; Xiong B; Zhou L; Fei Y; Shi C; Zhu X; Xie T; Wu Y
BMC Cancer; 2024 Mar; 24(1):387. PubMed ID: 38539150
[TBL] [Abstract][Full Text] [Related]
14. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
Liu J; Wang P; Shang L; Zhang Z; Tian Y; Chen X; Ma Y; Shao H
Hepatol Int; 2024 Apr; 18(2):595-609. PubMed ID: 37843788
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.
Wang BC; Kuang BH; Lin GH
Target Oncol; 2024 Mar; 19(2):203-212. PubMed ID: 38289445
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis.
Dawood ZS; Brown ZJ; Alaimo L; Lima HA; Shaikh C; Katayama ES; Munir MM; Moazzam Z; Endo Y; Woldesenbet S; Pawlik TM
HPB (Oxford); 2024 May; 26(5):618-629. PubMed ID: 38369433
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Hu L; Zheng Y; Lin J; Shi X; Wang A
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102061. PubMed ID: 36473632
[TBL] [Abstract][Full Text] [Related]
18. Effects of Short-Term Lenvatinib Administration Prior to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Tachiiri T; Minamiguchi K; Taiji R; Sato T; Toyoda S; Matsumoto T; Chanoki Y; Kunichika H; Yamauchi S; Shimizu S; Nishiofuku H; Marugami N; Tsuji Y; Namisaki T; Yoshiji H; Tanaka T
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730577
[TBL] [Abstract][Full Text] [Related]
19. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial.
Ren Y; Li Y; Cao M; Tang Y; Yuan F; Yang G; He Z; Shi Z; Su X; Yao Z; Deng M
Chin J Cancer Res; 2024 Apr; 36(2):114-123. PubMed ID: 38751440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]